Navigation Links
Spiriva has Closed the Gap in Patient Share Between Itself and Advair for the Treatment of COPD
Date:12/22/2009

WALTHAM, Mass., Dec. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.

"Surveyed U.S. primary care physicians (PCPs) expect to use more of Spiriva over the next two years while their enthusiasm around Advair is waning compared to last year's analysis," stated Decision Resources Analyst Amanda Puffer. "Almost 60 percent of PCPs say they will increase their use of Spiriva over the next two years and only eight percent think their use of the drug will decline. This is important to note because last year's analysis indicated that a lot of Advair's use was driven by PCPs."

The new report entitled Treatment Algorithms in Chronic Obstructive Pulmonary Disease also finds that the declining use of Advair may be due in part to increased use of AstraZeneca's Symbicort, which was approved for COPD in February of 2009. Patient-level claims data indicates that even prior to its approval, Symbicort was gaining ground in this market and compared to last year's analysis, Symbicort's patient share in the second line increased by 2.8 percentage points.

By combining patien
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
2. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
6. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
7. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
8. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
9. FDA researchers identify new MRI safety risk for patients with pacemakers
10. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  Merck KGaA, Darmstadt, ... top-quality high-tech products in the healthcare, life science and ... company Nano-C, their development and launch of promising new ... (OPV). Merck KGaA, Darmstadt, Germany , ... OPV sector. Novel derivatives: highly stable, easy ...
(Date:8/3/2015)... 3, 2015 According to a ... Cell Culture: Asia to Witness ... the global 3D cell culture market was valued at US$ 586.1 ... a CAGR of 29.1% to account for US$ 2,717.6 ... TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell culture refers ...
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
(Date:7/30/2015)... TX, USA (PRWEB) , ... July 30, 2015 ... ... and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , ... positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. ...
Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... Yondelis(R) sales network across Western Europe, BRACKNELL, ... services agreement with PharmaMar, a subsidiary of Zeltia ... sales team in Western,Europe to promote Yondelis(R), PharmaMar,s ... marketing authorization, will be,responsible for marketing the drug., ...
... new data,demonstrating that the investigational drug lacosamide, with ... therapy,significantly reduced the frequency of seizures and was ... up,to 5.5 years. The results of the two ... today at the 61st annual meeting of the ...
... LIFE. "Fertility & Diet" (p. 54). The latest chapter,of ... research on,how foods impact the odds of getting pregnant. ... M.D., and Patrick,J. Skerrett, authors of the new book ... weight control play in conception and weigh in on,their ...
Cached Biology Technology:Innovex to Promote PharmaMar's Yondelis(R) Cancer Treatment 2Innovex to Promote PharmaMar's Yondelis(R) Cancer Treatment 3UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients 2UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients 3UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients 4NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 2NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 3NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 4NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 5
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... research into the Earth,s paleoclimate history by NASA,s Goddard ... the potential for rapid climate changes this century, including ... is not abated. By looking at how the ... insight into a fundamental question raised by ongoing human-caused ...
... MADISON -- Shifting a fraction of truck-borne freight onto trains ... Midwest, according to researchers at the University of WisconsinMadison. ... to Erica Bickford, a graduate student in UWMadison,s Nelson Institute ... go about 150 miles on a gallon of diesel fuel. ...
... Medical School have made an important discovery about the ... on our understanding of how proteins regulate appetite control ... Zammit, Head of Metabolic and Vascular Health at Warwick ... palmitoyltransferase 1A, (CPT1) has a switch which is thrown ...
Cached Biology News:Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4For Midwesterners, more boxcars mean cleaner air 2
... hybridomas against a large variety of ... are provided with personalized project proposals ... developed by Covance remain exclusive property ... development project has four phases: immunization, ...
Cells are grown in triple flasks or roller bottles. Viability and growth data are generated from a parallel representative culture....
... Service The Human Genetic Cell Bank ... (EBV) immortalisation of human peripheral blood lymphocytes ... cell lines (LCLs). These cell lines are ... source of genomic DNA and RNA. ...
... optimized for maximum packaging efficiencies of T7Select ... extracts (> 109 pfu/g with control DNA) ... containing at least 5 107 recombinant ... made from a specially designed phage that ...
Biology Products: